These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Ashworth A; Rodrigues G; Boldt G; Palma D Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084 [TBL] [Abstract][Full Text] [Related]
5. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202 [TBL] [Abstract][Full Text] [Related]
6. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Bansal P; Rusthoven C; Boumber Y; Gan GN Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543 [TBL] [Abstract][Full Text] [Related]
7. Review of treatment options for oligometastatic non-small cell lung cancer. Folkert MR; Timmerman R Clin Adv Hematol Oncol; 2015 Mar; 13(3):186-93. PubMed ID: 26352427 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057 [TBL] [Abstract][Full Text] [Related]
9. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies]. Langer F; Helsberg K; Schütte WH; Leschinger MI Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886 [TBL] [Abstract][Full Text] [Related]
10. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer. Guerrero E; Ahmed M Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592 [TBL] [Abstract][Full Text] [Related]
11. Combined modality therapy of non-small cell lung cancers. Juretic A; Sobat H; Samija M Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559 [TBL] [Abstract][Full Text] [Related]
12. The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370 [TBL] [Abstract][Full Text] [Related]
18. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270 [TBL] [Abstract][Full Text] [Related]
19. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. Tibdewal A; Agarwal JP; Srinivasan S; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kannan S BMJ Open; 2021 Mar; 11(3):e043628. PubMed ID: 33727268 [TBL] [Abstract][Full Text] [Related]
20. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Bunn PA Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]